INKEF Capital, an investment group that assists and invests in technology-based companies in the Netherlands in a wide range of sectors such as life sciences, IT, nanotechnology and clean energy, has done an investment of € 7.5 million in Sapiens Steering Brain Stimulation (Sapiens). Sapiens is an emerging medical device company whose mission is to bring a revolutionized concept of Deep Brain Stimulation (DBS) to more patients who can benefit from this advanced treatment of degenerative or functional brain disorders, such as Parkinson's disease, dystonia and other currently emerging indications.

Sapiens' ambition is to improve the therapeutic outcome of DBS, to shorten and simplify the clinical procedure, and to improve patient comfort. Sapiens' high-resolution probe enables the reduction of stimulation-induced side-effects by precisely steering the tiny stimulation currents to the intended target area. The SureSuite products - SurePlan, SurePlace and SureTune - provide an integrated, image-based solution for planning and programming an optimal DBS treatment. SureStim, the Sapiens implant, is MRI-conditionally safe, and controls the steering.

With offices in Eindhoven, the Netherlands and Munich, Germany, Sapiens was founded in 2011. The Company is a spin-out of Royal Philips Electronics, and is backed by Wellington Partners, Edmond de Rothschild Investment Partners and Life Sciences Partners (LSP). Its Steering Brain Stimulation probe, implant and image-guided programming are based upon patents-pending technologies.

AKD set up a series of 'Chinese walls' between the teams that acted for Sapiens and INKEF Capital respectively.

François Koppenol led the AKD team that assisted INKEF Capital,which team also included Pauline Boiten and Nienke Bollen.

Matthijs Ingen-Housz of AKD assisted Sapiens and its management.